ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
November 20, 2024 08:00 ET | ImmuneSensor Therapeutics
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase 1b/2 clinical studies in patients with AGS, lupus and other cGAS-driven diseases ...
exagen-logo-black.png
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024 16:30 ET | Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Alumis.png
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
November 14, 2024 16:05 ET | Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
Alumis.png
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 13, 2024 16:05 ET | Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
New Logo v2.png
Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO
October 28, 2024 10:00 ET | Medicovestor Inc
Medicovestor secures 3 USPTO patents, advancing its innovative ADC platform and unique antibodies for enhanced cancer treatment and autoimmune potential.
Alumis.png
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
September 27, 2024 09:00 ET | Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
U.S. IVD And LDT For Autoimmune Diseases Market
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
September 24, 2024 10:29 ET | Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical...
Artiva Biotherapeutics Logo.jpg
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 29, 2024 16:05 ET | Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Transparency Market Research
Apheresis Market Size to Surge to USD 6.7 Billion by 2034, Driven by Strong Growth Momentum at 7.7% CAGR | Report by Transparency Market Research, Inc.
August 28, 2024 18:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 28, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global apheresis market...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
August 19, 2024 08:00 ET | ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...